Biorestorative Therapies (NASDAQ:BRTX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
BioRestorative Granted Type B Meeting with FDA to Discuss Accelerated BLA Approval Pathway for BRTX-100 in Chronic Lumbar Disc Disease
BioRestorative Therapies, Inc. (BRTX) Q3 2025 Earnings Call Transcript [Seeking Alpha]
BioRestorative Therapies Reports Third Quarter 2025 Financial Results and Provides Business Update
BioRestorative Therapies to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025